Author

P. Qu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 11 Organism:human· 9 Assay:proteomics· 6 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1

Frequent Co-Authors

S.-L. Liu· 9 shared Y.-M. Zheng· 9 shared C. Carlin· 8 shared E. M. Oltz· 8 shared L. J. Saif· 8 shared R. J. Gumina· 8 shared J. P. Evans· 7 shared K. Xu· 7 shared

Activity by Year

2019-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

S.-L. Liu

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants

P. Qu, K. Xu, J. N. Faraone, N. Goodarzi, Y.-M. Zheng, C. Carlin, J. S. Bednash, J. C. Horowitz, R. K. Mallampalli, L. J. Saif, E. M. Oltz, D. Jones, R. J. Gumina, S.-L. Liu

This study compares immune evasion, infectivity, and fusogenicity of SARS-CoV-2 variants BA.2.86 and FLip using neutralization assays and cell-based experiments.

bioRxiv · Sep 11, 2023Microbiology

Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3

J. N. Faraone, P. Qu, N. Goodarzi, Y.-M. Zheng, C. Carlin, L. J. Saif, E. M. Oltz, K. Xu, D. Jones, R. J. Gumina, S.-L. Liu

This study evaluates neutralization and fusion activity of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3, showing reduced neutralization by bivalent vaccines and highlighting the need for updated vaccine formulations.

bioRxiv · Aug 30, 2023Immunology

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants

P. Qu, J. N. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study evaluates neutralizing antibody escape by Omicron subvariants XBB.1.5, CH.1.1, and CA.3.1, showing near-complete escape from mRNA vaccines but partial rescue with bivalent boosters.

bioRxiv · Jan 16, 2023 · PreprintMicrobiology

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2

P. Qu, J. P. Evans, J. Faraone, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study evaluates neutralization resistance and immune evasion mechanisms of SARS-CoV-2 Omicron subvariants against various sera, identifying key mutations driving resistance.

bioRxiv · Oct 19, 2022 · PreprintMicrobiology

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants

P. Qu, J. P. Evans, C. Kurhade, C. Zeng, Y.-M. Zheng, K. Xu, P.-Y. Shi, X. Xie, S.-L. Liu

This study identifies mutations in the Omicron subvariant spike protein that reduce fusogenicity and increase endosomal entry, revealing mechanisms behind their immune evasion and pathogenesis.

bioRxiv · Oct 15, 2022 · PreprintMicrobiology

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant

P. Qu, J. P. Evans, Y.-M. Zheng, C. Carlin, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study investigates how the BA.2.75 SARS-CoV-2 variant evades neutralizing antibodies through specific mutations and shows enhanced cell-cell fusion.

bioRxiv · Aug 14, 2022Microbiology

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants

P. QU, J. N. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, S.-L. Liu

This study examines the durability of neutralizing antibody responses to SARS-CoV-2 BA.2.12.1 and BA.4/5 variants after mRNA booster vaccination, finding significant waning but stable responses compared to two-dose immunity.

bioRxiv · Jul 21, 2022 · PreprintMicrobiology

Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

P. Qu, J. P. Evans, J. N. Faraone, X. Zou, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. K. Mallampalli, L. J. Saif, E. M. Oltz, P. J. Mohler, R. J. Gumina, S.-L. Liu

This study compares the neutralization resistance, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants to other variants and finds increased resistance and fusogenicity linked to L452 mutations.

bioRxiv · May 16, 2022 · PreprintMicrobiology

Neutralization and Stability of SARS-CoV-2 Omicron Variant

Z. Cong, J. P. Evans, P. Qu, J. Faraone, Y.-M. Zheng, C. Carlin, J. S. Bednash, T. Zhou, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, K. Xu, R. J. Gumina, S.-L. Liu

This study investigates the immune evasion and transmissibility of the SARS-CoV-2 Omicron variant, showing significant immune evasion but restored neutralization with booster doses and increased transmissibility due to a more stable spike protein structure.

bioRxiv · Dec 16, 2021 · PreprintMicrobiology

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples

S. E. Larsen, B. J. Berube, T. Pecor, E. Cross, B. P. Brown, B. Williams, E. Johnson, P. Qu, L. Carter, S. Wren, E. Kepl, C. Sydeman, N. P. King, S. L. Baldwin, R. N. Coler

This paper qualifies ELISA and neutralization assays to measure SARS-CoV-2 humoral immunity using clinical samples, evaluating antibody titers and functional neutralization capacity.

bioRxiv · Jul 2, 2021Immunology

A systematic CRISPR screen reveals an IL-20/IL20RA-mediated peritoneal immune crosstalk to prevent the ovarian cancer metastasis

J. Li, X. Qin, J. Shi, X. Wang, T. Li, M. Xu, X. Chen, Y. Zhao, J. Han, Y. Piao, W. Zhang, P. Qu, L. Wang, R. Xiang, Y. Shi

The paper identifies IL20RA as a key factor preventing ovarian cancer metastasis through immune crosstalk with peritoneal mesothelial cells.

eLife · Jun 11, 2021Peer-reviewedCancer Biology

Neutrophilic granule protein is a novel murine LPS antagonist

J. Hong, P. Qu, T. R. Wuest, P. C. Lin

The paper identifies NGP as a secreted murine protein that inhibits LPS function by blocking its interaction with TLR4.

bioRxiv · Aug 13, 2019Immunology

Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma

A. Mikulasova, C. Ashby, R. G. Tytarenko, P. Qu, A. Rosenthal, J. A. Dent, K. R. Ryan, M. A. Bauer, C. P. Wardell, A. Hoering, K. Mavrommatis, M. Trotter, S. Deshpande, S. Yaccoby, E. Tian, , B. A. Walker

The paper identifies MYC rearrangements in multiple myeloma, showing they are complex and linked to overexpression of MYC and PVT1 through distinct DNA repair mechanisms.

bioRxiv · Jun 24, 2019Cancer Biology